Ying-Ming Jou

1.0k total citations · 1 hit paper
8 papers, 631 citations indexed

About

Ying-Ming Jou is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Ying-Ming Jou has authored 8 papers receiving a total of 631 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 3 papers in Genetics. Recurrent topics in Ying-Ming Jou's work include Advanced Breast Cancer Therapies (5 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Cancer-related Molecular Pathways (3 papers). Ying-Ming Jou is often cited by papers focused on Advanced Breast Cancer Therapies (5 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Cancer-related Molecular Pathways (3 papers). Ying-Ming Jou collaborates with scholars based in United States, Canada and Germany. Ying-Ming Jou's co-authors include Naoki Takezako, Kenshi Suzuki, Brian T. Rafferty, Jesús F. San Miguel, Mihaela Popa McKiver, Meletios Α. Dimopoulos, Paul G. Richardson, Mitsuo Hori, Michael Robbins and Philippe Moreau and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

Ying-Ming Jou

7 papers receiving 620 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

2018 364 citations Meletios Α. Dimopoulos, Dominik Dytfeld et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Ying-Ming Jou

Since Specialization

Citations

This map shows the geographic impact of Ying-Ming Jou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying-Ming Jou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying-Ming Jou more than expected).

Fields of papers citing papers by Ying-Ming Jou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying-Ming Jou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying-Ming Jou. The network helps show where Ying-Ming Jou may publish in the future.

Co-authorship network of co-authors of Ying-Ming Jou

This figure shows the co-authorship network connecting the top 25 collaborators of Ying-Ming Jou. A scholar is included among the top collaborators of Ying-Ming Jou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying-Ming Jou. Ying-Ming Jou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials 2025 ·Dermatology and Therapy ·Joseph F. Merola, Laura K. Ferris, Jeffrey M. Sobell, Howard Sofen, John Osborne, (unknown), Ying-Ming Jou, (unknown), (unknown), (unknown), Mark Lebwohl	1
2	Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis 2025 ·Clinical and Experimental Dermatology ·Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Tiago Torres, Zoran Popmihajlov, Ying-Ming Jou, Misti Linaberry, (unknown), C.E.M. Griffiths	0
3	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma breakdown → 2018 ·New England Journal of Medicine ·Meletios Α. Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying-Ming Jou, Suresh G. Shelat, Michael Robbins, Brian T. Rafferty, Jesús F. San Miguel	364
4	Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies 2017 ·British Journal of Cancer ·Monica Mita, Alain C. Mita, Jennifer L. Moseley, Jennifer Poon, Karen Small, Ying-Ming Jou, Paul T. Kirschmeier, (unknown), Yali Zhu, Paul Statkevich, (unknown), John Sarantopoulos, James M. Cleary, Lucian R. Chirieac, Scott J. Rodig, Rajat Bannerji, Geoffrey I. Shapiro	48
5	Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer 2013 ·Clinical Breast Cancer ·Monica Mita, Anil A. Joy, Alain C. Mita, Kamalesh K. Sankhala, Ying-Ming Jou, Da Zhang, Paul Statkevich, Yali Zhu, (unknown), Karen Small, Rajat Bannerji, Charles L. Shapiro	122
6	Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias 2013 ·Cancer Chemotherapy and Pharmacology ·Ivana Gojo, Mariola Sadowska, Alison Walker, Eric J. Feldman, Swaminathan P. Iyer, Maria R. Baer, Edward A. Sausville, Rena G. Lapidus, Da Zhang, Yali Zhu, Ying-Ming Jou, Jennifer Poon, Karen Small, Rajat Bannerji	74
7	Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL. 2011 ·Journal of Clinical Oncology ·Joseph M. Flynn, Justin A. Jones, Leslie A. Andritsos, Kristie A. Blum, (unknown), (unknown), Elizabeth Wiley, NA Heerema, Jennifer Poon, Karen Small, Ying-Ming Jou, (unknown), Paul Statkevich, M. R. Grever, Rajat Bannerji, John C. Byrd	10
8	A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results. 2011 ·Journal of Clinical Oncology ·Monica Mita, Akira Mita, Jennifer L. Moseley, Jennifer Poon, Karen Small, Ying-Ming Jou, Paul T. Kirschmeier, (unknown), Paul Statkevich, Kamalesh K. Sankhala, John Sarantopoulos, (unknown), Lucian R. Chirieac, Scott J. Rodig, Rajat Bannerji, Geoffrey I. Shapiro	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact